Search - tctmd.com

Displaying 301 - 320 of 1203

Sort: Relevancy | Date

News Daily News

Un Estudio Sugiere que la Revascularización de Arterias No Causantes Mejora el Estado de Salud de Pacientes STEMI

Todd Neale

November 04, 2015

News Daily News

Study Suggests Nonculprit Revascularization Enhances Health Status of STEMI Patients

Todd Neale

November 04, 2015

News Daily News

Battle Scars: Combat Injury Linked With Cardiovascular Risk

Caitlin E. Cox

November 04, 2015

News Industry News

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

November 02, 2015

News Industry News

Tryton Medical Files Pre-Market Approval Application with US FDA for Tryton Side Branch Stent

November 01, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Industry News

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

October 26, 2015

News Daily News

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

Todd Neale

October 26, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding

Presenter: Cindy L. Grines, Philip M. Urban

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Presenter: Bernard J. Gersh, Thomas F. Luscher, Clemens von Birgelen

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

Advertisement

Un Estudio Sugiere que la Revascularización de Arterias No Causantes Mejora el Estado de Salud de Pacientes STEMI

Study Suggests Nonculprit Revascularization Enhances Health Status of STEMI Patients

Battle Scars: Combat Injury Linked With Cardiovascular Risk

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

Tryton Medical Files Pre-Market Approval Application with US FDA for Tryton Side Branch Stent

Younger Women With STEMI More Likely Than Men to Die In-Hospital

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Guideline Update Boosts Nonculprit PCI, Knocks Down Aspiration Thrombectomy

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content